Floor H. M.
- Country
- The Netherlands
- Department
- Hematology
Research Overview
- Phase 1 Evaluation of BMS-986416 with and without Nivolumab in Patients with Solid Tumors
- Pharmacokinetic-Guided Dosing of Emicizumab in Patients with Congenital Hemophilia A: A Non-Inferiority Study
- Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Study of Elenestinib in Patients with Indolent Systemic Mastocytosis and Smoldering Systemic Mastocytosis
Data & Insights
Has run more than one trial at 8 of 54 partner sites.
Specializations
Hematology Research
Specializes in investigating treatment approaches for congenital haemophilia A, with particular focus on innovative dosing strategies for preventive therapies. The investigator studies personalized treatment protocols using pharmacokinetic-guided dosing methods to optimize patient outcomes.
- Bleeding Prevention Protocols
- Individualized Treatment Approaches
- Prophylactic Therapy Optimization
Contributes to advancing therapeutic strategies for managing joint and muscle bleeds in hemophilia patients.
Oncology Research
Conducts investigations in the field of solid tumor treatment, exploring novel therapeutic agents. The investigator's work encompasses evaluation of innovative treatment combinations, including immunotherapy approaches.
- Solid Tumor Therapeutics
- Combination Therapy Assessment
- Novel Treatment Evaluation
Focuses on developing new therapeutic strategies for various types of solid tumors through clinical investigation.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.